Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is Next quarterly earnings (projected) on October 22, 2026, a projected date rather than a confirmed one. There are 6 upcoming events on record.
Cash runway is approximately 7.3 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
Across 28 concluded trials, 43% reached completion rather than being terminated or withdrawn.
| Date | Event | Type | Phase |
|---|---|---|---|
| October 22, 2026 est. | Next quarterly earnings (projected) | Earnings | — |
| December 15, 2026 | A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma | Trial Milestone | Phase 2/Phase 3 |
| December 15, 2026 | Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Trial Milestone | Phase 2 |
| April 15, 2027 | Selinexor and Backbone Treatments of Multiple Myeloma Patients | Trial Milestone | Phase 1/Phase 2 |
| June 15, 2027 | A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia | Trial Milestone | Phase 2 |
| January 15, 2028 | A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM. | Trial Milestone | Phase 2 |
Track KPTI alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open KPTI in the trackerTrial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.